Paper Details

  1. Home
  2. Paper Details

Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies.

Author: ChenXuejun, CiminoEvan, GongXiaohua, KuligowskiMichael E, LiuXiang, LiuXing, McGeeRyan, YeleswaramSwamy

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Topical ruxolitinib cream for atopic dermatitis did not lead to systemic plasma concentrations associated with adverse effects commonly seen with oral JAK inhibitors.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Pathogenesis of atopic dermatitis (AD) involves the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway. A cream formulation of ruxolitinib, a potent selective JAK1/JAK2 inhibitor, was developed for topical delivery. METHOD: Pharmacokinetic data were obtai...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8200345/

データ提供：米国国立医学図書館（NLM）

A Topical Solution: Exploring the Pharmacokinetics of Ruxolitinib Cream for Atopic Dermatitis

We're exploring a new approach to treating atopic dermatitis, a chronic skin condition characterized by inflammation, itchiness, and dryness. The researchers are investigating the pharmacokinetics of ruxolitinib cream, a topical medication that targets the JAK/STAT pathway involved in the development of atopic dermatitis. They conducted a [研究手法] to assess the absorption, distribution, metabolism, and elimination of ruxolitinib cream in patients with atopic dermatitis. Their findings suggest that topical ruxolitinib cream is well-tolerated and does not lead to significant systemic exposure, potentially minimizing the risk of adverse effects associated with oral JAK inhibitors.

A Targeted Approach: Delivering Relief Directly to the Source

This research presents a potential breakthrough in treating atopic dermatitis. By targeting the inflammation directly at the skin level, ruxolitinib cream offers a localized approach to treatment, potentially reducing the risk of systemic side effects. This could be a game-changer for patients with atopic dermatitis seeking a safe and effective treatment option.

Managing Atopic Dermatitis: A Holistic Approach

While topical ruxolitinib cream shows promise, it's important to remember that managing atopic dermatitis often requires a multi-pronged approach. This can include moisturizing the skin regularly, avoiding irritants, and maintaining a healthy lifestyle. By taking a holistic approach, individuals with atopic dermatitis can work towards improving their skin health and well-being.

Dr. Camel's Conclusion

This research is like a camel discovering a new oasis in the desert, offering a refreshing and targeted approach to treating atopic dermatitis. Ruxolitinib cream could potentially be a valuable tool for individuals seeking relief from this challenging skin condition.

Date :
  1. Date Completed 2021-09-13
  2. Date Revised 2023-11-11
Further Info :

Pubmed ID

33982267

DOI: Digital Object Identifier

PMC8200345

Related Literature

Article Analysis
・Effects of ruxolitinib topical
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.